Background: Detection of hepatocellular carcinoma (HCC) in patients with chronic liver disease (CLD) is difficult. We investigated the use of comprehensive proteomic profiling of sera to differentiate HCC from CLD. Methods: Proteomes in sera from 20 CLD patients with ␣-fetoprotein (AFP) <500 g/L (control group) and 38 HCC patients (disease group) were profiled by anionexchange fractionation (first dimension), two types (IMAC3 copper and WCX2) of ProteinChip ® Arrays (second dimension), and time-of-flight mass spectrometry (third dimension). Bioinformatic tests were used to identify tumor-specific proteomic features and to estimate the values of the tumor-specific proteomic features in the diagnosis of HCC. Cross-validation was performed, and we also validated the models with pooled sera from the control and disease groups, serum from a CLD patient with AFP >500 g/L, and postoperative sera from two HCC patients. Results: Among 2384 common serum proteomic features, 250 were significantly different between the HCC and CLD cases. Two-way hierarchical clustering differentiated HCC and CLD cases. Most HCC cases with advanced disease were clustered together and formed
or sera from cancer patients and control individuals, attempts have been made to identify cancer-associated proteins. HCC, bladder carcinoma, breast carcinoma, renal cell carcinoma, and lung carcinoma have been studied with use of traditional two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) (3 ) . Although various approaches have been developed for protein expression analysis (4 ) , the combination of 2D-PAGE and mass spectrometry (MS) has been the most successful (4 -7 ) . There are, however, limitations in the 2D-PAGE approach. Hydrophobic, strongly acidic, or strongly basic proteins are poorly resolved by 2D-PAGE (4 ) . The utility of this technology is also limited by an inability to accurately monitor proteins that are present at very low abundance (4 ) .
Surface-enhanced laser desorption/ionization time-offlight (SELDI-TOF) MS is a novel non-electrophoresisbased proteomic technology that was introduced by Hutchens and Yip (8 ) and forms the core technology of the SELDI ProteinChip ® Biomarker System (9 ) . In this system, proteins are retained on a solid-phase chromatographic surface (i.e., the ProteinChip Array) and are subsequently ionized and detected by TOF MS. The ProteinChip System can be used in protein profiling of various biological materials, such as serum, urine, and cell lysates (9 -13 ) . It has been shown to be useful in the discovery of potential diagnostic markers for cancers such as prostate (10 ) , ovarian (11 ) , and breast cancer (12 ) . Profiling of low-molecular-mass proteins/peptides (Ͻ20 kDa) revealed that the relative abundances of five peptides with specific m/z values in the SELDI-TOF spectrum formed a unique "proteomic signature" for the highly sensitive and specific diagnosis of ovarian cancer (11 ) . Similarly, profiling of low-molecular-mass proteins/peptides demonstrated that nine low-molecular-mass peptides with m/z values Ͻ10 000 formed a proteomic signature for the detection of prostate cancer with a sensitivity of 83% (10 ) .
Recently we showed that artificial neural networks (ANNs) trained with the serum concentrations of six serologic protein markers, all of which have molecular masses Ͼ20 kDa, could improve the identification of HCC (14 ) . It has also been shown that, coupled with significant analysis of microarray (SAM) for gene filtering, ANNs can distinguish between global gene expression profiles of Barrett esophagus and esophageal cancer (15 ) . We have now extended these observations and the proteomic signature concept to the proteomic analysis of serum proteins with molecular masses up to 200 kDa.
The objective of this study was to determine whether comprehensive proteomic profiling (molecular mass, 0.5-200 kDa) of serum coupled with bioinformatic analysis methods originally designed for gene expression data could identify a proteomic signature for effectively differentiating HCC from CLD. To obtain comprehensive proteomic profiles of sera from 0.5 to 200 kDa, we used an automated high-throughput, multidimensional strategy involving anion-exchange fractionation, two different ProteinChip surfaces, and the SELDI ProteinChip Biomarker System. For bioinformatic analyses, we used SAM for protein filtering, two-way hierarchical clustering, and ANN. As a proof of principle, our results show that the multidimensional ProteinChip analysis strategy permits comprehensive serum proteomic profiling. It allows the identification of tumor-specific proteomic signatures for differentiation of HCC from CLD with high sensitivity and specificity and may even permit the identification of HCC subtypes.
Materials and Methods patient materials
With patients' consent, we collected clotted blood samples from HCC patients and patients with CLD only at presentation at the Joint Hepatoma Clinic at the Prince of Wales Hospital between October 1997 and November 1998; all blood samples were stored at Ϫ70°C before assay. Patients with HCC were diagnosed according to standard clinical criteria as reported previously (16 ) . All HCC cases were confirmed histologically. The cancer group consisted of 38 serum samples from patients with primary HCC at different clinical stages (TNM classification of the American Joint Committee on Cancer): stage I (n ϭ 6), stage II (n ϭ 8), stage III (n ϭ 17), and stage IV (n ϭ 7). Specimens were obtained before treatment. The median age of the HCC patients was 58 years (range, 33-78 years). Among the HCC patients, 18 had serum AFP Ͼ500 g/L and 20 had serum AFP Ͻ500 g/L. The control group consisted of 20 serum samples from CLD patients with AFP Ͻ500 g/L. All CLD patients were followed for at least 18 months for any sign of HCC to exclude individuals with asymptomatic HCC. One serum sample (CLD21) from a CLD patient with AFP Ͼ500 g/L (905 g/L) was also analyzed in this study. Postoperative sera were also collected from two HCC patients. After tumor resection, one (labeled as RHCC1) had residual disease, whereas the other (labeled as RHCC2) was in complete remission. After each serum sample was analyzed individually, serum samples from the 18 HCC patients with AFP Ͼ500 g/L and those from the 20 HCC patients with AFP Ͻ500 g/L were pooled as samples HCCP1 and HCCP2, respectively, whereas the 20 serum samples from the control group were pooled as sample CLDP1.
anion-exchange fractionation (first-dimension separation)
Anion-exchange fractionation can be regarded as a replacement of the first-dimensional separation, isoelectric focusing, in the 2D-PAGE technology. Both technologies separate proteins on the basis of their pI values. Q Ceramic HyperDF ion-exchange resin (Biosepra SA) was used to fractionate the samples. All 
seldi analysis of serum fractions (second-and third-dimensional analyses)
Each serum fraction was analyzed on immobilized metal ion affinity capture (IMAC3) ProteinChip Arrays (Ciphergen), loaded with copper, and weak cationic exchange (WCX2) ProteinChip Arrays (Ciphergen) in duplicate. Different ProteinChip surfaces (second dimension) helped to identify very low abundance proteins. The IMAC3 copper and WCX2 ProteinChip surfaces preferentially retain different groups of proteins according to their physiochemical properties (9 ) . The IMAC3 copper and WCX2 arrays were equilibrated twice with 150 L of binding buffer (0.5 mol/L NaCl buffered with 100 mmol/L sodium phosphate, pH 7, for IMAC3 copper arrays and with 100 mmol/L sodium acetate, pH 4, for WCX2 arrays). Each fraction was diluted in the appropriate binding buffer (5-fold for IMAC copper arrays; 10-fold for WCX2 arrays). We applied 100 L of the diluted fraction to each ProteinChip Array and incubated the array with shaking at room temperature for 30 min. After the incubation, each array was washed three times with binding buffer and rinsed twice with deionized water. After the arrays were air-dried, we added sinapinic acid matrix in 500 mL/L acetonitrile-5 mL/L trifluoroacetic acid to each array. The ProteinChip Arrays were read on a ProteinChip PBS II reader of the ProteinChip Biomarker System to measure the masses and intensities of the protein peaks (Ciphergen). The mass spectrometric analysis (third dimension) with the ProteinChip PBS II reader can be regarded as a replacement of the second dimensional separation, sodium dodecyl sulfate-PAGE, in the 2D-PAGE technology. Both technologies separate proteins on the basis of their molecular masses. We averaged 235 laser shots for each array with masses ranging from 0.5 to 200 kDa. All mass spectra were normalized to have the same total ion current. The CVs of the peak intensities were Ͻ15% (manufacturer's information). Common protein peaks were picked by the Biomarker Wizard TM function of the ProteinChip Software (Ciphergen). Average peak intensities of the duplicate measurements were used in later bioinformatic analyses.
sam protein filtering
The protein filtering process was performed with SAM (17 ) . Given the group identities, SAM was used to compare the peak intensities of the proteomic features between the cancer (38 HCC cases) and control (20 CLD cases with AFP Ͻ500 g/L) groups and to identify the proteomic features that were significantly different at a median false significant value Ͻ0.000005. The control group was defined as "1", whereas the tumor group was defined as "2". "Two classes unpaired data" was selected as the data type, and permutations were performed 1000 times.
two-way hierarchical clustering analysis
The significant differential proteomic features that were identified from SAM were subjected to two-way hierarchical clustering analysis. Before the analysis, the median intensity of each significant proteomic feature was normalized to equal 1, and then all the normalized intensity data were subtracted by 1. After this data processing, the intensity data would be positive when they were greater than the median intensity and negative when they were lower. The processed data for the significant proteomic features and the serum samples were subjected to twoway hierarchical clustering analysis with use of Cluster and TreeView (18 ) . Spearman rank correlation was used to calculate the distance, and complete linkage clustering was performed.
ann model development
An ANN model was developed as described previously (14 ) . The ANN algorithm applies artificial intelligence to classification, pattern recognition, and prediction (14, 15 ). An ANN model consists of processing elements (neurones), which are organized in layers. From a training data set, an ANN model can "learn" the association patterns between the input variables and outcomes and then apply these patterns to new cases. The ANN model was developed with EasyNN (Ver. 8.1; Stephen Wolstenholme). The development method was of the feed-forward type, and the networks were trained by weighted back-propagation. Both learning rate and momentum were optimized automatically by the software. The ANN model was composed of three layers, one input layer, one hidden layer, and one output layer. There were seven nodes in the middle, hidden layer. The input variables for the development of the ANN model were the relative levels of the significant differential proteomic features, whereas the output variable was the diagnostic score (range, 0 -1.0000) of each case. During training of the ANN model, the diagnostic scores were defined as 0.0000 and 1.0000 for the CLD cases and HCC cases, respectively. The training was stopped when all output errors were Ͻ0.02. The maximum number of training cycles was restricted to 300 to prevent overtraining. Using the developed ANN model, we performed 10-fold cross-validation to estimate the ANN diagnostic scores for each HCC and CLD case. The whole data set (38 HCC and 20 CLD cases) was randomly divided into 10 subsets of equal size. The model was then trained 10 times, each time leaving out one of the subsets from training but using the omitted subset as an independent blinded test set to assess the performance of the model. ROC curves were constructed by calculating the sensitivities and specificities of tests at different cutoff points of the ANN diagnostic scores for differentiating HCC cases from CLD cases. The developed ANN model was also used to classify the unseen cases, including the two cases with resected HCC (RHCC1 and RHCC2), the CLD case with AFP ϭ 905 g/L (CLD21), and the unseen pooled sera (HCCP1, HCCP2, and CLDP1).
Results

identification of specific serum proteomic features associated with hcc
We found 2384 proteomic features among the serum samples: 1087 by use of the IMAC3 copper ProteinChip Array and 1297 by use of the WCX2 ProteinChip Array. To search for the serum proteins/polypeptides significantly different between the HCC and CLD cases, we performed SAM for protein filtering. By setting the median value of a false significant number to Ͻ0.000005, we identified 88 proteomic features that were significantly higher in the HCC patient sera and 162 proteomic features that were significantly lower. Thus, in total, we found 250 potential serologic markers for the identification of HCC. The five most significantly higher and the five most 
identification of hcc and its subtypes by twoway hierarchical clustering
We performed two-way hierarchical clustering analysis (two-dimensional complete linkage), based on the 250 differential proteomic features. The clustering algorithm separated HCC and CLD cases into two major clusters (Fig. 2) . Most of the typical CLD cases with AFP Ͻ500 g/L (19 of 20 cases) and case CLD21 (with increased serum AFP) were grouped together. The pooled serum samples HCCP1, HCCP2, and CLDP1 were also aligned correctly together with the HCC and CLD cases. The resected case with residual tumor (RHCC1) was aligned with the HCC cases, whereas the complete remission case (RHCC2) was aligned with the CLD cases, indicating its nontumor nature. This also suggests that the identified serum proteomic signatures in the HCC patients, which disappeared when a tumor was completely removed, were tumor specific. The majority of HCC cases with advanced disease (stage III and IV) were clustered together, forming two HCC subgroups, A and B (Fig. 2 and Table 2 ). There were significantly more cases with lymph node invasion or distant metastasis in these two subgroups ( Fig. 2 and Table 2 ). Our results therefore indicate that advanced HCCs and metastatic tumors could be identified on the basis of the serum proteomic profiles, without knowledge of the clinical information of the cases, and suggest the potential of using comprehensive serum proteomic profiling to classify HCC into different subtypes.
ann model for differentiation of hcc from cld
To integrate the clinical values of the 250 differential proteomic features for discrimination of HCC from CLD, we developed an ANN model from these proteomic features of the cancer and control cases for diagnostic score calculation. We performed 10-fold cross-validation analysis to estimate the diagnostic performance of the resulting ANN model. The diagnostic scores of the HCC cases [mean (SD), 0.922 (0.358)] were significantly higher (P Ͻ0.0005, Mann-Whitney test) than those of CLD cases [0.177 (0.246)]. ROC curve analyses showed that the ANN diagnostic score was useful in differentiating HCC and CLD cases regardless of serum AFP concentrations (Fig.  3) . The area under ROC curve was 0.914 [95% confidence interval, 0.823-1.006; P Ͻ0.0005] for all cases (Fig. 3A) , whereas the area was 0.954 (95% confidence interval, 0.881-1.027; P Ͻ0.0005) for cases with nondiagnostic serum AFP concentrations (Ͻ500 g/L; Fig. 3B) .
At an ANN diagnostic score cutoff of 0.8500, the mean (SE) sensitivity and specificity were 92 (4)% (35 of 38 HCC cases) and 90 (7) A negative control ANN model was developed using 250 randomly selected insignificant proteomic features as input variables and was examined by 10-fold crossvalidation. As expected, the ROC curve analysis showed that the negative control ANN model was much less useful in differentiating between HCC and CLD cases (0.780; 95% confidence interval, 0.643-0.916; P ϭ 0.001). At an ANN diagnostic score cutoff of 0.8500, the mean (SE) sensitivity and specificity of the negative control ANN model were only 68 (8)% (26 of 38 HCC cases) and 65 (11)% (13 of 20 control cases), respectively. Our results strongly indicate that (a) an ANN algorithm can be used to combine the diagnostic values of the 250 differential proteomic features, (b) combined use of the 250 differential proteomic features allows the detection of HCC at a sensitivity and a specificity of ϳ90%, and (c) the resulting ANN model can identify HCC cases with nondiagnostic AFP concentrations at a sensitivity of ϳ95%.
Discussion
In this study, we have described a high-throughput, multidimensional strategy that uses the SELDI ProteinChip Biomarker System for comprehensive profiling of serum proteomes and have identified tumor-specific proteomic signatures that differentiated HCC and CLD cases. The ANN that was developed with use of the differential proteomic features was useful in differentiating HCC from CLD, even when serum AFP concentrations were within the diagnostic gray region. Differentiation of HCC with nondiagnostic AFP from CLD is particularly important in Southeast Asian countries, including Hong Kong and China, because Ͼ80% of HCC cases arise in patients with preexisting liver cirrhosis (2 ) . The present study is of the case-control type, and there may be a positive bias; additional studies are thus needed to formally elucidate the diagnostic accuracy.
Various high-throughput technologies have been deClinical Chemistry 49, No. 5, 2003 veloped for measurement of the expression profiles of numerous genes simultaneously and have been used to study gene expression patterns in various cancer tissues, including leukemia, colon carcinoma, breast cancer, and HCC (19, 20 ) . On the basis of such gene expression profiles, tumor subtypes with distinctive prognostic features have been identified (21 ) . Unique gene expression profiles have been observed in metastatic HCC (22 ) . Because proteins are gene products, it is logical to expect that specific proteomic profiles/patterns may be also associated with specific types or even subtypes of tumors.
In the present study, comprehensive serum proteomic profiling enabled us to identify HCC patient subgroups with significantly more advanced HCCs and metastatic tumors, without knowledge of the clinical information. This suggests that protein expression profiles may differ between early and advanced HCCs and between metastatic and nonmetastatic tumors, leading to different serum proteomic profiles. Our study therefore suggests that comprehensive serum proteomic profiling can classify cancers into different subtypes. The identification of cancer subtypes is important in estimating prognosis and in the selection of patients who are likely to be responsive to a particular treatment. Comprehensive serum proteomic profiling may be particularly invaluable when tumor tissue is not available for histologic examination. Furthermore, the correct classification of two resected HCC cases, one with residual tumor and one without, as a HCC case and a noncancer case suggests the possibility of using comprehensive serum proteomic profiling for monitoring treatment response and tumor recurrence. In the future, proteomic profiling, gene expression profiling, and single-nucleotide polymorphism profiling may complement each other in unraveling an individual's response to therapy (23, 24 ) .
The SELDI ProteinChip Biomarker System has been used previously to identify single or multiple tumorspecific biomarkers in various cancers, including prostate (10 ), ovarian (11 ) , and breast cancer (12 ) . When peptides and proteins below m/z 20 000 (i.e., molecular mass Ͻ20 kDa) were analyzed, increased concentrations of five peptides with specific m/z values were found in the sera of patients with ovarian cancer (11 ) . These five peptides formed a proteomic signature, which allowed detection of ovarian cancer at 100% sensitivity and 95% specificity. Similarly, profiling of low-molecular-mass proteins/peptides identified a proteomic signature comprising nine low-molecular-mass peptides with m/z values Ͻ10 000 (i.e., molecular mass Ͻ10 kDa) for the detection of prostate cancer at a sensitivity of 83% (10 ) . Our multidimensional strategy allowed us to identify Ͼ200 potential tumor markers in the sera of patients with HCC. The number of potential tumor markers thus may have been underestimated in previous studies that used SELDI-TOF MS technology. Consistent with the studies of ovarian Fig. 3 . ROC curve analysis of the ANN diagnostic score in discriminating between HCC and CLD cases. (11 ) and prostate cancer (10 ), we also found tumorspecific peptides/polypeptides with molecular masses Ͻ20 kDa. Furthermore, our study indicates that there are significant numbers of tumor-specific proteins with molecular masses Ͼ20 kDa. More experiments are needed to identify the nature of the 250 proteins. Nevertheless, because each protein has a unique m/z value, these proteins can be unambiguously detected and quantified in patient sera, even without knowledge of their protein identities. These markers form tumor-specific proteomic signatures for the detection of HCC at a sensitivity and specificity of ϳ90%.
The clinical applications of proteomics have been hindered by limitations of both proteomic technologies (4, 23 ) and bioinformatic tools (13, 25 ) . In this study, we have shown that a multidimensional strategy involving anion-exchange fractionation and the SELDI ProteinChip Biomarker System allows comprehensive proteomic profiling. We have also shown that cDNA/oligonucleotide microarray data analysis tools, including SAM gene filtering, two-way hierarchical clustering, and ANNs, are useful in identifying proteomic signatures associated with HCC.
Compared with gene expression microarray data, the computational analysis tools for proteomic data are still underdeveloped (13, 25 ) . Genetic algorithms (11 ), selforganizing cluster analysis (11 ) , and discrete wavelet transform analysis (13 ) have all been used to compare ProteinChip Array data between the control and test groups, but the results generated from all these analytical tools are difficult to interpret. The present study shows that comprehensive ProteinChip Array data can be readily analyzed with the algorithms commonly used for gene expression data analysis, including SAM gene filtering and two-way hierarchical clustering. SAM uses repeated permutations of the data to determine whether the expression of any gene/protein is significantly related to a response. The cutoff for significance is determined by the user based on false discovery rate. The false discovery rate is the number of falsely called genes/proteins divided by the number of differential genes/proteins in the original data. In other words, the false discovery rate provides information on the percentage of nonsignificant genes/proteins one can expect to find in the result list of differentially expressed genes/proteins (17 ) . This allows identification of proteomic features that are "genuinely" significantly different between HCC patients and control groups and avoids multiple testing problems. The twoway hierarchical clustering dendrogram allows examination of the correlations among cases or proteomic features. Furthermore, our results indicate that the combination of ANN and data filtering with SAM is not only useful in distinguishing between global gene expression profiles (15 ) , but also in distinguishing between comprehensive proteomic profiles of sera from cancer patients and individuals without cancer. The computation of a diagnostic score by an ANN model provides an easy way to interpret tumor-specific proteomic signatures for the detection of HCC.
In conclusion, the present study provides the first evidence that comprehensive proteomic profiling from 0.5 to 200 kDa can be performed by the SELDI ProteinChip Biomarker System and can be analyzed and interpreted in a way similar to gene expression data. Although future studies are needed for less biased elucidation of the diagnostic accuracy, this study suggests that tumor-specific proteomic signatures are present in the sera of patients with HCC and have potential as a clinical tool for the detection or classification of individual cancers or even tumor subtypes with high sensitivity and specificity. Similar strategies may be applied to analyze the proteomes of tumor tissues or biological fluids from patients with other cancer types.
